Trinity College Dublin

Skip to main content.

Top Level TCD Links

Sharon O'Toole
Snr Experimental Officer, Obstetrics
Senior Research Fellow, Histopathology

Biography

Sharon O'Toole is a senior research fellow in Trinity College Dublin working in the area of ovarian cancer. She qualified with a BSc Hons in UCG in 1994 and then completed an MSc Biotechnology in 1996. Having worked in industry she then returned to research and completed a PhD in Trinity College in 2003. She has gained enormous experience in the area of ovarian cancer and has played a major role in the development of studies in gynaecological cancer. She was instrumental in establishing the DISCOVARY consortium which is a multidisciplinary and trans- institutional consortium dedicated to addressing the problems of ovarian and uterine cancer. The consortium manages the largest ovarian cancer bioresource in the country. The consortium has now merged to form INNOVATION- the Irish National Network for Ovarian Cancer Collaboration which has brought together the medical, research and charity organisations involved in ovarian cancer in Ireland. Her research interests centre around diagnostic and prognostic biomarkers and understanding the fundamental biology of the metastatic cascade and circulating tumour cells. She has been successful in identifying diagnostic and prognostic biomarkers for ovarian cancer and her ultimate aim is to translate these into the clinic. She has presented at both national and international conferences and published in peer-reviewed journals. She works closely with the 3 ovarian cancer charities in Ireland whose mission is to improve outcomes for ovarian cancer in Ireland. She was part of the organising committee of the first World Ovarian Cancer Day on May 8th in 2013 and this has now become an annual event.

Publications and Further Research Outputs

Peer-Reviewed Publications

Ffrench B, Gasch, Hokamp K, Spillane C, Blackshields G, Mahgoub TM, Bates M, Kehoe L, Mooney A, Doyle R, Doyle B, O'Donnell D, Gleeson N, Hennessy BT, Stordal B, O'Riain C, Lambkin H, O'Toole S, O'Leary JJ, and Gallagher MF., CD10-/ALDH- cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell network. Cell Death & Disease , Cell Death and Disease, 2017 Journal Article, 2017 TARA - Full Text

B Jose, S O'Toole, R Forster, JJ O'Leary. , Smart Nanomotors: Towards in-vivo Sensing., Laboratory Investigation , USCAP, 97, ((S1)), 2017, pp530A- Published Abstract, 2017

Petch S, Norris L, O'Toole S, Gleeson N, Abu Saadeh F. , Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice., Thrombosis Research, 145, 2016, p126 - 128 Journal Article, 2016

Abu Saadeh, F, Langhe R, Galvin DM, O Toole SA, O'Donnell DM, Gleeson N, Norris LA, Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. , Thrombosis Research, 139, 2016, p135 - 141 Journal Article, 2016 DOI

White C, Bakhiet S, Bates M, Keegan H, Pilkington L, Ruttle C, Sharp L, O' Toole S, Fitzpatrick M, Flannelly G, O' Leary JJ, Martin CM. , Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study. , Cytopathology, 27, (4), 2016, p269 - 276 Journal Article, 2016

Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin C, O'Donnell DM, D'Arcy T, O'Leary J, O'Toole S, A novel serum microRNA panel to discriminate benign from malignant ovarian disease, Cancer Letters, 356, ((2ptB)), 2015, p628-636- Journal Article, 2015 DOI

Martin CM, Astbury K, Kehoe L, O'Crowley JB, O'Toole S, O'Leary JJ. , The Use of MYBL2 as a Novel Candidate Biomarker of Cervical Cancer. , Methods Mol Biol, 1249, 2015, p241 - 251 Journal Article, 2015

McEvoy LM, O'Toole SA, Spillane CD, Martin CM, Gallagher MF, Stordal B, Blackshields G, Sheils O, O'Leary JJ, Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer., BMC cancer, 15, 2015, p547 Journal Article, 2015

Busschots S, O'Toole S, O'Leary JJ, Stordal B, Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines., MethodsX, 2, 2015, p8-13 Journal Article, 2015

Keegan Helen, Pilkington Loretto, McInerney Jamie, Jeney Csaba, Benczik Márta, Cleary Sinead, von Bunau Gunther, Turner Michael, D'Arcy Tom, O' Toole Sharon, Borbála Pal-Szenthe, Borbála Kaltenecker, Johanna Mózes, Anettc Kovács, Agnes Solt, Bolger Noel, O'Leary John, Martin Cara., Human papillomavirus detection and genotyping, by HC2, Full-Spectrum HPV and Molecular Beacon Real-Time HPV assay in an Irish colposcopy clinic, Journal of Virological Methods, 2014 Journal Article, 2014 TARA - Full Text

d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ., The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer., PLoS One. , 9, (6), 2014, pe100816- Journal Article, 2014 TARA - Full Text DOI

Busschots S, O'Toole S, O'Leary JJ, Stordal B. , Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells, Experimental Cell Research, 2014, p1 - 14 Journal Article, 2014 DOI TARA - Full Text

Noninvasive Biomarkers in Ovarian Cancer in, editor(s)Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz , Cancer Biomarkers: Minimal and Noninvasive Early Diagnosis and Prognosis , CRC press, 2014, [O'Toole, SA, Ancuta, E, Langhe, R, Cahill, DJ, Murphy, M, Martin, C, McEvoy, L, Spillane, C, Sheils, O, Petricoin, E, Liotta, L, O'Leary JJ] Book Chapter, 2014

Abu Saadeh, Norris L, O'Toole S, Mohamed BM, Langhe R, O'Leary J, Gleeson N, Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk., Thrombosis Research, 132, 2013, p627 - 634 Journal Article, 2013 DOI

Abu Saadeh F, Norris L, O'Toole S, Gleeson N, Venous thromboembolism in ovarian cancer: Incidence, risk factors and impact on survival., European Journal of Obstetrics & Gynecology and Reproductive Biology , 170, (1), 2013, p214 - 218 Journal Article, 2013 Other

White C, Keegan H, Pilkington L, Ruttle C, Kerr P, Sharp L, O'Toole S, Turner M, Prendiville W, D'Arcy T, Fitzpatrick M, Lenehan P, Flannelly G, O'Leary JJ, Martin CM, Evaluation of the clinical performance of the cobas 4800 HPV test in patients referred for colposcopy., Journal of clinical microbiology, 51, (10), 2013, p3415-7 Journal Article, 2013 DOI TARA - Full Text

Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA, Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening., International journal of molecular sciences, 14, (1), 2013, p2085-103 Journal Article, 2013 TARA - Full Text DOI

Murphy MA, O'Connell DJ, O'Kane SL, O'Brien JK, O'Toole S, Martin C, Sheils O, O'Leary JJ, Cahill DJ, Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays, Journal of Proteomics, 75, (15), 2012, p4668 - 4675 Journal Article, 2012 TARA - Full Text

Gallagher MF, Heffron CC, Laios A, O'Toole SA, Ffrench B, Smyth PC, Flavin RJ, Elbaruni SA, Spillane CD, Martin CM, Shelis OM, O'Leary JJ. , Suppression of Cancer Stemness p21-regulating mRNA and microRNA Signatures in Recurrent Ovarian Cancer Patient Samples. , Journal of Ovarian Research, 5, (1), 2012, p2- Journal Article, 2012 DOI

Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A, Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer., The Journal of pathology, 226, (5), 2012, p746-55 Journal Article, 2012

Pilkington L, Keegan H, O'Toole S, Singh S, Cleary S, Prendiville W, Darcy T, Turner MJ,, Von Bunau G, Anglim M, O'Leary JJ, Martin CM. , The utility of HPV testing in predicting disease recurrence post colposcopic treatment for cervical intraepithelial neoplasia. , Modern Pathology/Laboratory Investigations, United Stated and Canadian Academy of Pathology, San Antonio, Texas, February 26-March 4, 91, (Supplement 1S), 2011, pp263A- Meeting Abstract, 2011

Karl Egan., Darragh Crowley., Paul Smyth, Sharon O'Toole, Cathy Spillane, Cara Martin, Michael Gallagher, Aoife Canney, Lucy Norris, Niamh Conlon, Lynda McEvoy2, Brendan Ffrench2, Britta Stordal, Helen Keegan, Stephen Finn, Victoria McEneaney, Alex Laios, Jens Ducre, Eimear Dunne, Leila Smith, Michael Berndt, Orla Sheils, Dermot Kenny, John O'Leary, Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells, PLoS ONE, 6, (10, e26125), 2011 Journal Article, 2011 TARA - Full Text

Ovarian Cancer Chemoresistance in, editor(s)Dr. rer. nat. Manfred Schwab , Encyclopedia of Cancer, SpringerReference, 2010, [O'Toole SA, O'Leary JJ] Book Chapter, 2010 URL

Gallagher MF, Flavin RJ, Elbaruni SA, McInerney JK, Smyth PC, Salley YM, Vencken SF, O'Toole SA, Laios A, Lee MY, Denning K, Li J, Aherne ST, Lao KQ, Martin CM, Sheils OM, O'Leary JJ, Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients., Journal of ovarian research, 2, 2009, p19 Journal Article, 2009 DOI TARA - Full Text

Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy in, Methods Mol Biol, 2009, pp333 - 359, [Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ] Book Chapter, 2009 DOI

Flavin, R.J., Smyth, P.C., Laios, A., O'Toole, S.A., Barrett, C., Finn, S.P., Russell, S., (...), O'Leary, J.J. , Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma, Modern Pathology , 22, (2), 2009, p197-205 Journal Article, 2009 DOI

Laios, A., O'Toole, S.A., Flavin, R., Martin, C., Ring, M., Gleeson, N., D'Arcy, T., (...), O' Leary, J.J. , An integrative model for recurrence in ovarian cancer , Molecular Cancer, 7, 2008, part. no. 8 Journal Article, 2008 DOI

Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ., Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients., Modern Pathology, 21, (6), 2008, p676 - 684 Journal Article, 2008 URL

Laios, A., O'Toole, S., Flavin, R., Martin, C., Kelly, L., Ring, M., Finn, S.P., (...), O'Leary, J. , Potential role of miR-9 and miR-223 in recurrent ovarian cancer , Molecular Cancer, 7, 2008, part. no. 35 Journal Article, 2008 TARA - Full Text DOI

O'Toole SA, Sheppard BL, Laios A, O'Leary JJ, McGuinness EP, D'Arcy T, Bonnar J., Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity?, Gynecological Oncology, 104, (2), 2007, p345 - 351 Journal Article, 2007 URL

O'Toole SA, Dunn E, Sheppard BL, Klocker H, Bektic J, Smyth P, Martin C, Sheils O, O'Leary JJ., Genome wide analysis of DNA in endometrial cancer using comparative genomic hybridisation microarrays. , International Journal of Gynaecological Cancer , 16, (2), 2006, p834 - 842 Journal Article, 2006 URL

O'Toole SA, Sheppard BL, Sheils O, O'Leary JJ, Spengler B, Christoffel V. , Analysis of DNA in endometrial cancer cells treated with phyto-estrogenic compounds using comparative genomic hybridisation microarrays., Planta Medica, 71, (5), 2005, p435 - 439 Journal Article, 2005 URL

O'Toole SA, Dunn E, Sheppard BL, Sheils O, O'Leary JJ, Wuttke W, Seidlova-Wuttke, D, Oestrogen regulated gene expression in normal and malignant endometrial tissue. , Maturitas, 51, (2), 2005, p187 - 198 Journal Article, 2005 URL

O'Toole SA, Sheppard BL, McGuinness EP, Gleeson NC, Yoneda M, Bonnar J, The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. , Cancer Detection and Prevention , 27, (1), 2003, p47 - 54 Journal Article, 2003 URL

O'Toole SA, Sheppard BL, McGuinness E, Gleeson NC, Bonnar J., Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy., International Journal of Gynaecological Cancer, 11, (5), 2001, p365 - 371 Journal Article, 2001 URL

O'Toole S, McGuinness E, Sheppard B, Bonnar J., Plasminogen activators and inhibitors in ovarian adenocarcinomas., International Journal of Gynaecological Cancer , 9, 1999, p61 - 66 Journal Article, 1999 URL

Sulaiman, G, Cooke A, Ffrench B, Gasch C, Abdullai OA, O'Connor K, Elbaruni S, Blacksheilds G, Spillane C, Keegan H, McEneaney V, Knittel R, Rogers A, Jeffery IB, Doyle B, Bates M, d'Adhemar C, Lee M, Campbell EL, Moynagh P, Higgins DG, O'Toole S, O'Neill L, O'Leary JJ and Gallagher MF. , MyD88 is an essential component of retinoic acid induced differentiation in human pluripotent embryonal carcinoma cells. , Cell Death & Differentiation Journal Article,

Non-Peer-Reviewed Publications

Abu Saadeh F, O'Toole S, Gleeson N, Norris L, Peak ant-Xa levels following LMWH (tinzaparin) prophylaxis in gynaecological cancer patients post surgery, Thrombosis Research, 7th Internation Conference on Thrombosis & Hemostatis Issues in Cancer, , Bergamot Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014 Meeting Abstract, 2014

Ibrahim N, Norris L, O'Toole S, McHugh T, Gleeson N, Does extended thromboprophylaxis help reduce the incidence of venous thromboembolism in gynaecological cancer patients?, Thrombosis Research, 7th Internation Conference onal Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014 Published Abstract, 2014

Abu Saadeh. F, Norris. L, O' Toole, Gleeson. N., Assessing the risk and mortality of venous thromboembolism in ovarian cancer., International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012 Meeting Abstract, 2012

Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, Gleeson. N., ETP as a marker for venous thromboembolism in gynaecologial cancer patients post surgery, International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012 Published Abstract, 2012

Abu Saadeh F, Norris L, O'Toole S, Langhe R, O'Leary JJ, Gleeson N., Does tissue factor and tissue factor pathway inhibitor over-expression play a role in the development of venous thromboembolism in ovarian cancer patients?, Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, ((Suppl 1)), Elsevier, 2012 Published Abstract, 2012

Abu Saadeh F, Norris L, O'Toole S, Langhe R, Gleeson N., Procoagulant activity in patients with gynecological malignancies and the effect of neoadjuvant chemotherapy , Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, (Suppl 1), Elsevier, 2012 Published Abstract, 2012

Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, O' Leary. J, Gleeson. N. , Why is venous thromboembolism is a common complication of ovarian cancer? , International Journal of Gynecological Cancer , 14th Biennial Meeting of the International Gynecological Cancer Society. , Vancouver, Canada, October 2012, 22, (Suppl 3), 2012 Published Abstract, 2012

Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, Gleeson. N, Endogenous thrombin potential as a marker for venous thrombosis in ovarian cancer., International Journal of Gynecological Cancer , 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012 Published Abstract, 2012

SA O'Toole, A Laios, BL Sheppard, NC Gleeson, T D'Arcy, EPJ McGuinness, J Bonnar, O Sheils and JJ O'Leary. , Potential predictors of chemotherapy response in ovarian cancer how do we define chemosensitivity?, Laboratory Investigation, United States and Canadian Society of Pathology, Atlanta, USA, Feb 2006, 86, (Suppl 1), Nature, 2006, pp190A Meeting Abstract, 2006

A Laios, SA O'Toole, BL Sheppard, NC Gleeson, T D'Arcy, E PJ McGuinness, M Ring, O Sheils and JJ O'Leary, Molecular profiling of primary versus recurrent ovarian serous papillary adenocarcinomas. , Laboratory Investigation, United States and Canadian Society of Pathology, Atlanta, USA, Feb 2006, 86, (Suppl 1), Nature, 2006, pp185A Meeting Abstract, 2006

CM Martin, K Astbury, R Henfrey, O Sheils, M Gallagher, C Heffron, C Logan, SA O'Toole, JJ O'Leary, miRNA expression signatures in cervical cancer, Journal of RNAi and Gene Silencing, RNAi2006: Advances in RNA Interference Research, St Anne's College, Oxford, United Kingdom, March 2006, 2, (2), 2006 Meeting Abstract, 2006

Laios A, O'Toole SA, Sheppard BL, Gleeson NC, D'Arcy T, McGuinness EPJ, Ring M, Sheils O, Smyth P, O'Leary JJ., Recurrent ovarian cancer cDNA signatures., Centenary Meeting of the Pathological Society of Great Britain and Ireland , Manchester, July 2006, 2006 Meeting Abstract, 2006

Laios A, O'Toole SA, Sheppard BL, Gleeson NC, D'Arcy T, McGuinness EPJ, Ring M, Sheils O, O'Leary JJ. (ed.), Irish Association for Cancer Research, Galway, Ireland, March 2006, 2006 Proceedings of a Conference, 2006

O'Toole S, Laios A, Sheppard B, Smyth P, O'Regan E, Sheils O, O'Leary J. , Expression profiling of endometrial stromal cells treated with estradiol and phytoestrogens. , 20th European Congress of Pathology, Paris, Sept 2005, 2005 Meeting Abstract, 2005

O'Toole SA, Laios A, Sheppard BL, Gleeson NC, D'Arcy T, Mc Guinness EPJ, Bonnar J, Sheils O, O'Leary JJ. , Potential Predictors of Chemotherapy Response in Ovarian Cancer., Irish gynaecological oncology society, Belfast, 2005, 2005 Meeting Abstract, 2005

A Laios, SA O'Toole, B Sheppard, N Gleeson, T D'Arcy, E PJ McGuinness, M Ring, O Sheils and JJ O'Leary. , Transcriptome profiling of primary and recurrent ovarian cancers, Junior Obstetrics and Gynaecology Society, Dublin, Nov 2005, 2005 Meeting Abstract, 2005

O'Toole SA, Laios A, Sheppard BL, Gleeson NC, D'Arcy T, Mc Guinness EPJ, Bonnar J, Sheils O, O'Leary JJ. , Angiogenesis markers in ovarian cancer act as prognostic markers but not indicators of chemotherapy response, Pathological Society of Great Britain and Ireland, Newcastle, UK, July 2005, 2005 Meeting Abstract, 2005

O'Toole SA, Sheppard BL, D'Arcy T, Mc Guinness EPJ, Gleeson NC, Bonnar J, Sheils O, O'Leary JJ. , Multidrug resistance gene only plays a role in some ovarian cancers, Irish Association for Cancer Research, Kilkenny, Ireland, March 2005, 2005 Meeting Abstract, 2005

O'Toole SA, Sheppard BL, D'Arcy T, Mc Guinness EPJ, Gleeson NC, Bonnar J, Sheils O, O'Leary JJ. , Angiogenesis in Ovarian Cancer does not predict response to chemotherapy., Irish Association for Cancer Research, Kilkenny, Ireland, March 2005, 2005 Meeting Abstract, 2005

SA O'Toole, BL Sheppard, P Smyth, C Martin, O Sheils, JJ O'Leary, B Spengler, V Christoffel, Genome wide analysis of DNA in endometrial cells treated with phytoestrogens using comparative genomic hybridisation microarrays, 5th International Symposium on Women's Health and Menopause, Florence, Italy, Apr 2004, 2004 Meeting Abstract, 2004

SA O'Toole, E Dunn, BL Sheppard, P Smyth, C Martin, O Sheils, JJ O'Leary, J. Bektic, H. Klocker. , Genome wide analysis of DNA in endometrial cancer using comparative genomic hybridisation microarrays. , 5th International Symposium on Women's Health and Menopause, Florence, Italy, Apr 2004, 2004 Meeting Abstract, 2004

SA O'Toole, E Dunn, BL Sheppard, O Sheils, JJ O' Leary, W Wuttke, D. Seidlova-Wuttke. , Oestrogen regulated gene expression in normal and malignant endometrial tissue. , Irish gynaecological oncology society, Cork, Ireland, 2004 Meeting Abstract, 2004

SA O'Toole, E Dunn, BL Sheppard, O Sheils, JJ O' Leary, W Wuttke, D. Seidlova-Wuttke. , Oestrogen regulated gene expression in normal and malignant endometrial tissue. , 5th International Symposium on Women's Health and Menopause, Florence, Italy, Apr 2004, 2004 Meeting Abstract, 2004

O'Toole SA, Sheppard BL, McGuinness EPJ, Gleeson NC, Bonnar J, Predicting the response of gynaecological tumours to chemotherapy. , Anticancer Research , 24, (2A), 2004, p533 - 534 Journal Article, 2004

O'Toole SA, Dunn E, Sheppard BL, Klocker H, Bektic J, Smyth P, Martin C, Sheils O, O'Leary JJ. , Genome wide analysis of DNA in endometrial cancer using comparative genomic hybridisation microarrays, Irish gynaecological oncology society,, Cork, Ireland, 2004 Meeting Abstract, 2004

O'Toole SA, Sheppard BL, Sheils O, Smyth P, Martin C, O'Leary JJ, Spengler B, Christoffel V. , Genome wide analysis of DNA sequence copy number in endometrial cells treated with phytoserms using comparative genomic hybridisation microarrays. , Irish Association for Cancer Research, Kilkenny, Ireland, Apr 2003, 2003 Meeting Abstract, 2003

O'Toole SA, Sheppard BL, McGuinness EPJ, Gleeson NC, Yoneda M, Bonnar J., Determining the response of gynaecological tumours to chemotherapy using an MTS cytotoxicity assay in combination with an explant culture technique, British Journal of Cancer , 86, (Suppl 1), 2002, pS46 - S46 Journal Article, 2002

O'Toole S, Sheppard B.L., Bonnar J, McGuinness E, Gleeson N, Cell Culture drug sensitivity/resistance testing of malignant gynaecological tumours. , British Journal of Obstetrics and Gynaecology , 107, (6), 2000, p818 - 819 Journal Article, 2000

O'Toole S, Sheppard B, Bonnar J, McGuinness E. , Fibrinolysis in Ovarian Carcinomas. , Joint IACR/ISMO Cancer Research Meeting, Belfast, 1999, 1999 Meeting Abstract, 1999

O'Toole S, Sheppard BL, Bonnar J, McGuinness E, Gleeson N, Cell Culture drug sensitivity/resistance testing of malignant gynaecological tumours., Irish Journal of Medical Science, 168, (Suppl 3), 1999, pp35 - 35 Meeting Abstract, 1999

O'Toole S, Chemosensitivity Testing of Gynaecological Tumours, 1st International Postgraduate Student Conference., Dublin, 1998, 1998 Meeting Abstract, 1998

Research Expertise

Description

-Early diagnostics in ovarian cancer -Chemoresistance in ovarian cancer Chemosensitivity/Resistance testing of malignant gynaecological tumours -Examination of Fibrinolytic systems of malignant gynaecological tumours -Examination of angiogenesis in ovarian cancers. -Examination of multidrug resistance genes in gynaecological tumours. -Estrogen regulated genes in endometrial cancer. -PhytoSERMs and Endometrial Cancer

Projects

  • Title
    • Identification of novel biomarkers in recurrent/chemoresistant ovarian cancer
  • Summary
    • Ovarian cancer is one of the most common cancers affecting women and is often detected in the advanced stage of the disease, resulting in a high mortality rate. This is because the symptoms of ovarian cancer are not recognised immediately, the molecular pathobiology of ovarian disease is poorly understood and sensitive screening tests are not currently available. Treatment usually involves surgery followed by chemotherapy. While many women respond well initially, a worrying number of women will face a recurrence of disease, often with the tumour becoming less amenable to chemotherapy over time. Understanding the biological mechanisms underlying recurrence of ovarian cancer and addressing chemoresistance is of the utmost importance for improving treatment and outcome of the disease. Recurrence represents the "true killer" among ovarian cancer patients and identification of novel molecular markers present in recurrent tumours is urgently required. Using cDNA microarrays, we will carry out gene expression profiling between primary and recurrent ovarian cancers from different patients with the same histology and from the same patients with different histology aiming to identify potential biomarkers of recurrence. Using TaqMan PCR techniques, selected targets will be further validated to correlate with microarray results. Signatures from both cohorts will be also validated against an independent set of serous papillary ovarian adenocarcinomas, the most common histological subtype. Using real-time RT-PCR, we will also examine the patterns of dysregulation of miRNAs in recurrent ovarian cancer and we will elucidate potential mechanisms responsible for this dysregulation. We will observe for any possible intersections between our transcriptomic and miRNA targets. We will also investigate the in vitro effects of selected targets in platinum sensitive and resistant cell lines.
  • Funding Agency
    • Royal City of Dublin Hospital Trust Fund
  • Date From
    • Oct 05
  • Date To
    • Oct 08
  • Title
    • A Consortium of researchers dedicated to understanding and treatment of ovarian cancer: The DISCOVARY Consortium
  • Summary
    • We have established an international trans-institutional multidisciplinary consortium [DISCOVARY] to address the problem of ovarian cancer. Our current work is focussed on identifying transcriptome, proteome and regulatory signatures which characterise early (Stage I), advanced (Stage III-IV), recurrent, chemoresistant and chemosensitive ovarian cancer and which can be used in a clinical setting to improve the diagnosis, treatment and management of this disease In addition, we believe that hypoxia plays a central role in the emergence of the chemoresistant phenotype in ovarian cancer patients. As part of our translational discovery pipeline, we have established the following specific objectives for this study: A. Extension and maintenance of a human ovarian tissue and serum bioresource network in Ireland, with the establishment of international collaborative link B. Generation of a novel human ovarian library proteome resource [OVA-1] C. Construction of a serum antibody profile in ovarian cancer D. Validation of a proteome map of borderline and early [stage I] ovarian cancer E. Construction of a transcriptome and miRNA translational control map of early, recurrent, non-recurrent and chemo-resistant ovarian cancer F. Formulation of diagnostic, prognostic and therapeutic validation pipelines G. Patient specific lab-on-a-chip devices to be used in therapeutic monitoring, bio-discovery and novel chemotherapeutic drug discovery H. Uncoupling hypoxia and chemoresistance in ovarian cancer I. Understanding blood-borne mechanisms involved in growth and spread of ovarian cancer J. Understanding cancer stem cells in ovarian cancer The consortium has been fortunate to receive funding from the Emer Casey Foundation. Family and friends of Emer established the foundation following her untimely death from ovarian/uterine cancer in June 2006.
  • Funding Agency
    • Emer Casey Foundation
  • Date From
    • Oct 08
  • Title
    • Chemosensitivity testing in gynaecological cancers
  • Funding Agency
    • Bristol-Myers Squibb/Enterprise Ireland
  • Date From
    • 1999
  • Date To
    • 2000

Keywords

Gynaecology oncology; Obstetrics/Gynecology; Oestregens in age related urogenital diseases

Recognition

Memberships

Member of European Association for Cancer Research. Member of Irish Association for Cancer Research


Last updated 21 September 2016 Paul Smyth (Email).